{"id":50335,"date":"2022-06-27T12:45:37","date_gmt":"2022-06-27T11:45:37","guid":{"rendered":"https:\/\/touchoncology.com\/?post_type=media_gallery&p=50335"},"modified":"2022-06-27T12:45:37","modified_gmt":"2022-06-27T11:45:37","slug":"50335","status":"publish","type":"media_gallery","link":"https:\/\/touchoncology.com\/lymphoma\/conference-hub\/50335\/","title":{"rendered":"Stephen Ansell, ASCO 2022: ECHELON-1, brentuximab vedotin plus chemotherapy for classical Hodgkin lymphoma"},"content":{"rendered":"
The ECHELON-1 study compared the experimental brentuximab vedotin plus chemotherapy (A+AVD) to standard ABVD chemotherapy in patients with classical Hodgkin lymphoma. Dr Stephen Ansell <\/b>(Mayo Clinic, Rochester, MN, USA) discusses the design and findings of the study as well as what was learned and how this will impact the treatment paradigm.\u00a0<\/span><\/p>\n The abstract entitled ‘First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III\/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1’ (Abstract number 7503<\/a>) was presented at the ASCO<\/a> annual meeting,<\/span>\u00a0June 3-7, 2022.<\/span><\/p>\n Questions<\/strong>:<\/span><\/p>\n 1. Could you give us a brief overview of the ECHELON-1 study and its findings? (0:15)<\/p>\n 2. What have we learned from the 6-year follow up data? (1:17)<\/p>\n 3. Which patients are likely to benefit most from brentuximab vedotin plus chemotherapy, and in whom is it contraindicated? (2:44)<\/p>\n 4. What will be the impact of these findings on the treatment paradigm for Hodgkin lymphoma? (4:38)<\/p>\n Disclosures<\/strong>: Stephen Ansell has received grant\/research support from ADC Therapeutics, Affimed, BMS, Pfizer, Regeneron, SeaGen and Takeda and is on the advisory board for Affimed.<\/span><\/p>\n Support<\/strong>: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.<\/span><\/p>\n